BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors [Reuters]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Reuters
BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors | Reuters Reuters Staff 1 Min Read April 24 (Reuters) - Nektar Therapeutics: * NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS * NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL EACH MAINTAIN GLOBAL COMMERCIAL RIGHTS TO THEIR RESPECTIVE INVESTIGATIONAL MEDICINES * NEKTAR THERAPEUTICS - NEKTAR AND TAKEDA WILL SPLIT COSTS RELATED TO CLINICAL TRIAL * NEKTAR THERAPEUTICS - FIRST TRIAL IS EXPECTED TO START IN SECOND HALF OF 2018 * NEKTAR - FIRST TRIAL TO EVALUATE COMBINATION OF EVERY 3-WEEK SCHEDULE OF NKTR-214 WITH ORAL DAILY DOSES OF TAK-659 IN PATIENTS WITH NON-HODGKIN LYMPHOMA Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at Jefferies Financial Group Inc. from $0.50 to $1.00. They now have a "hold" rating on the stock.MarketBeat
- Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 3/19/24 - Form D
- 3/15/24 - Form SC
- 3/14/24 - Form 3
- NKTR's page on the SEC website